drugset / Trial / NCT00540670

A Double-Blind Study of E5555 in Japanese Subjects With Coronary Artery Disease

NCT00540670

Phase 2 Completed 240 enrolled Eisai Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to assess the safety and tolerability of E5555 in Japanese subjects with coronary artery disease.

Timeline

Start
2007-10
Primary completion
2009-03
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Atopaxar Small molecule 50 mg Oral
Subject Atopaxar Small molecule 100 mg Oral
Subject Atopaxar Small molecule 200 mg Oral